Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma
- Cite this article as:
- Dreicer, R., Smith, D.C., Williams, R.D. et al. Invest New Drugs (1999) 17: 183. doi:10.1023/A:1006331518952
- 18 Downloads
This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only 3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma.